Molbio Diagnostics IPO

Listed on the exchange

Molbio Diagnostics priced its issue at ₹807.00 and began trading on 17 August 2026.

The dates that matter

An Indian IPO runs on a fixed calendar. Bidding stays open for three working days, the allotment is finalised the next working day, and the shares begin trading the day after that.

Issue dates

1. Anchor investor biddingCompleted

   7 August 2026

   One day before the public window, for institutional anchors.

2. Bidding opensCompleted

   10 August 2026

3. Bidding closesCompleted

   12 August 2026

4. Basis of allotmentCompleted

   13 August 2026

5. Refunds initiatedCompleted

   14 August 2026

6. Shares credited to DematCompleted

   14 August 2026

7. Listing on the exchangeCompleted

   17 August 2026

Grey market premium

Grey market premium is the price traders quote among themselves for shares that have not listed yet. Below is the full day-by-day record we hold for this issue, not only the latest figure, because the movement across the bidding window says more than any single day does.

About Molbio Diagnostics

Molbio Diagnostics Ltd. makes portable molecular testing equipment and the kits that run on it. The company incorporated in 2000 and operates from Verna, Goa. Its main product is the Truenat platform, a battery-operated real-time PCR system that gives test results in under an hour. The company sells testing devices and earns recurring revenue from the kits and consumables used with each device. Truenat covers more than 30 diseases through 43 assays, including tuberculosis, COVID-19, HIV, Hepatitis B and C, and HPV. Molbio sells to government health programs, hospitals, diagnostic laboratories and international health organisations. It runs manufacturing sites in Goa, Visakhapatnam and Bengaluru, and sells in over 90 countries through 33 international distributors. The company also offers radiology, digital pathology and breast health screening through subsidiary Prognosys, associate OptraScan and partner UE Lifesciences. As of 31 March 2026, it employed 1,225 permanent staff.

Promoters

• Sriram Natarajan
• Chandrasekhar Bhaskaran Nair
• Sangeetha Sriram
• Shiva Sriram
• Sowmya Sriram
• Exxora Trading LLP

Financial highlights

The last three fiscal years as the offer document states them. Reading across a row shows whether the figure has grown, which is why the years run left to right.

Figures are in ₹ crore and reproduced from the offer document, covering Mar 2024 to Mar 2026. A dash means the document does not state that figure for that period. A fiscal year ending March is labelled by its closing month, and where the document states a figure on a different basis the label here follows the document rather than normalising it.

Key ratios

Valuation and return ratios calculated from the issuer's financials. These are the figures the issue price is usually judged against, and the offer document carries the working behind each one.

Ratios are stated as published. A ratio that is absent here was not stated in the document, and is not the same as a ratio of zero.

What the money is for

Every issue states its objects in the offer document. These are reproduced from it, largest first, so you can see where most of the raise is going.

• Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.

  ₹105.54 Cr

• Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and

  ₹72.28 Cr

• Issue Expenses

  ₹59.54 Cr

• General Corporate Purposes

  ₹9.47 Cr

Peer comparison

The offer document compares the issuer against listed companies in the same business, on earnings, book value and return on net worth. Molbio Diagnostics is the first row.

Reproduced from the peer comparison in the offer document. A dash means the document does not state that figure for that company. It is absent, not zero. Ratios are reported on the basis named in the document, which is not always the same period for every company.

Who gets what share

SEBI fixes how much of a book-built issue each investor category can be allotted. This is the split for this issue as stated in the offer document.

Percentages are reproduced as text from the offer document. A dash means the document does not state an amount for that category. Categories are labelled using the document's own terms, which differ slightly between issues.

Questions people ask

Sources

• National Stock Exchange of India. "Upcoming and current public issues, with live bid quantities." The exchange publishes the bidding figures this page is built from, and is the authority on them. Accessed 15 September 2026.
• BSE. "Public issues — current and forthcoming." The second exchange carrying this issue, and the second source for its bidding data. Accessed 15 September 2026.
• Securities and Exchange Board of India. "Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018." The regulation that sets the issue process, the categories and the allotment rules. Accessed 15 September 2026.
• Molbio Diagnostics issue particulars are compiled and published by DematOpen, refreshed every 30 minutes, and reviewed by the editorial team. The record was last updated 15 September 2026. The offer document and the registrar above are the primary sources for anything you intend to act on.